Single-ventricle physiology correlates with higher short-term mortality among adult congenital heart disease transplant recipients


UCLA-led research finds that among adult congenital heart disease (CHD) transplant recipients, single-ventricle physiology correlated with higher short-term mortality. But 10-year conditional survival was similar for biventricular and most single-ventricle CHD patients, and notably better for biventricular CHD patients compared to non-CHD heart transplant recipients.


Congenital heart disease (CHD) is a heterogeneous group of structural abnormalities that can be thought of as spectrum from very severe lesions requiring multiple surgeries to others that are not as high risk. Historically, single-ventricle CHD subtypes were all considered higher risk than their biventricular counterparts, which would lead to some transplant centers being hesitant to perform a heart transplant in these patients.


The researchers analyzed National (Nationwide) Inpatient Sample and Organ Procurement and Transplantation Network data sets for 2005-2020. Of 382 adult heart transplant recipients with congenital heart disease (CHD), 185 (48%) had single-ventricle physiology. Compared to patients with biventricular CHD, those with single-ventricle CHD showed significantly reduced survival at 1 year (80% vs 91%) and 10 years (54% vs 71%). Among patients who survived the first post-transplantation year, biventricular CHD patients exhibited similar 10-year survival as single-ventricle patients, except for those with hypoplastic left heart syndrome (79% vs 71%). Additionally, biventricular CHD transplant recipients showed significantly better 10-year conditional survival compared to their non-CHD counterparts (79% vs 68%).

Study limitations include a lack of granularity in the data sets which would have allowed analysis of all aspects involved in transplantation. Also, there were no common patient identifiers between the two data sets, so the researchers had to rely on novel probability linkage methodology to match the records.


The findings have significant implications toward patient selection and listing strategies, easing concerns related to heart transplantation in adults with CHD and destigmatizing most subtypes of single-ventricle CHD.


"To date there have been no large-scale, national studies looking at survival outcomes in single-ventricle patients, despite the extensive availability of transplantation data dating back to 1987," said lead author Dr. Syed Shahyan Bakhtiyar, visiting research scientist in the UCLA Division of Cardiac Surgery and a general surgery resident at the University of Colorado. "Consequently, not only have patients and their families lacked essential prognostic insights, but surgeons and transplant teams have also been limited in their ability to make fully informed decisions about listing practices and transplantation for these patients. Our findings not only alleviate concerns associated with heart transplantation in adult CHD patients as a whole, but also work towards destigmatizing most subtypes of single-ventricle CHD."


Study co-authors are Sara Sakowitz, Konmal Ali, Dr. Nikhil Chervu, Arjun Verma, Dr. Ming-Sing Si, and Dr. Peyman Benharash of UCLA, and Dr. David D'Alessandro of Massachusetts General Hospital.


The study is published in the peer reviewed Journal of the American College of Cardiology.

Journal reference:

Bakhtiyar, S. S., et al. (2023). Survival After Cardiac Transplantation in Adults With Single-Ventricle Congenital Heart Disease. Journal of the American College of Cardiology.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough in aging research: Blocking IL-11 extends lifespan and improves health in mice